Sheena Jonathan sold $3.2M of NTRA
Sheena Jonathan sold 9,150 shares of Natera, Inc. (NTRA) at an average of $351.49 ($348.02–$356.87, $3.22M total) across 7 trades over 2026-09-15 to 2026-09-16 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Insider sales often trigger short‑term trading activity; however, the director's remaining stake remains sizable.
Market read
Routine insider sale with modest size; limited trading relevance.
What to watch
Potential upcoming clinical data releases could offset any negative sentiment from the insider sale.
Background
Form 4 filing discloses insider transactions; Natera is a publicly traded genetic testing company.
Ticker impact
Director Sheena Jonathan sold 9,150 shares for $3.2M via a 10b5‑1 plan, reducing her stake to 221,314 shares.
Potential modest dip of 1‑2% in short term.
Director sales are routine but the size ($3.2M) is notable for a mid‑cap biotech; market may view it as a mild negative cue.
Market effects
May prompt scrutiny of other biotech insider activity but no sector-wide impact.
Limited to US biotech investors.
Low
Counterpoint
The sale could be a portfolio rebalancing unrelated to company outlook; price may remain stable.
Key entities
- DirectorSheena Jonathan
Natera director who sold shares via 10b5‑1 plan.
- CompanyNatera, Inc.
Provider of genetic testing and reproductive health services.
